ASN 2019 preview – fears grow that roxadustat could come up short
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
SITC 2019 preview – Pieris joins the quest for a better Herceptin
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Triple meeting – Mirati avoids the worst-case scenario
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Triple meeting – targeted focus validates Merus’s change of tack
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
EADV 2019 – Pfizer carves out a niche for abrocitinib
One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.
SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Esmo 2019 makes for a disappointing read-across to biotech
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Vantage Esmo 2019 roundup
Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical…
Esmo 2019 – Clovis is running out of waves to catch
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.